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Autosomal recessive hereditary spastic paraplegia (ARHSP)
with thin corpus callosum (TCC) is a common and clinically
distinct form of familial spastic paraplegia that is linked to the
SPG11 locus on chromosome 15 in most affected families.
We analyzed 12 ARHSP-TCC families, refined the SPG11
candidate interval and identified ten mutations in a previously
unidentified gene expressed ubiquitously in the nervous system
but most prominently in the cerebellum, cerebral cortex,
hippocampus and pineal gland. The mutations were either
nonsense or insertions and deletions leading to a frameshift,
suggesting a loss-of-function mechanism. The identification
of the function of the gene will provide insight into the
mechanisms leading to the degeneration of the corticospinal
tract and other brain structures in this frequent form
of ARHSP.
ARHSP-TCC clinically manifests as spastic paraplegia, usually begin-
ning during infancy or puberty (and up to 23 years), preceded by
learning difficulties1–3. Cognitive impairment is first noticed in child-
hood and progresses insidiously to severe functional disability of a
frontal type over a period of 10–20 years2. Some affected individuals
develop a pseudobulbar involvement, with dysarthria, dysphagia and
upper limb spasticity, associated with bladder dysfunction and signs of
predominantly axonal, motor or sensorimotor peripheral neuropa-
thy3. Positron emission tomography shows cortical and thalamic
glucose hypometabolism. Magnetic resonance imaging shows TCC
that predominates in the rostral third, with hyperintensities in
periventricular white matter and cerebral cortical atrophy predomi-
nating in the frontal region.
The major ARHSP-TCC locus, SPG11 (refs. 4–6), was recently
restricted to the region between markers D15S968 and D15S132
(refs. 7–9). This disorder is found in several ethnic groups, particularly
in countries around the Mediterranean basin and in Japan5–9. TCC is
not restricted to SPG11, however10–13.
In the current study, all available members of 12 ARHSP-TCC
families were genotyped using 34 microsatellite markers in the
candidate interval for SPG11 and the adjacent and overlapping loci
for SPG21 (ref. 12) and agenesis of corpus callosum with polyneuro-
pathy (ACCPN)14. Maximal positive multipoint LOD scores ranging
from 0.60 to 3.85, which corresponded to the maximal expected values
in the pedigrees, were obtained in ten families in the SPG11 interval
(Supplementary Fig. 1 online). The combined multipoint LOD score
reached the value of 17.32 in these families. Linkage was not
conclusive in the two remaining kindreds. Haplotype reconstructions
in two consanguineous families (FSP672 and FSP221) with strong
evidence for linkage to SPG11 (LOD scores of 2.60 and 3.85) further
restricted the region most likely to contain the responsible gene to
the 3.2-cM homozygous region between D15S778 and D15S659
(Supplementary Figs. 1 and 2 online). This was the only region
that segregated with the disease in a genome scan performed in the
most informative family (FSP221).
This interval containsB40 genes, according to the National Center
for Biotechnology Information (NCBI) and Ensembl databases. We
analyzed 18 genes (Fig. 1) in SPG11 index patients by direct sequenc-
ing of all exons and their splicing sites but did not find any disease-
causing mutations in 17 of them. When we analyzed the KIAA1840
gene, also known as FLJ21439, we found ten different mutations in 11
of these families (Fig. 1b). All mutations (four nonsense mutations,
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four small deletions and two small insertions) were in the coding
sequence and were at the homozygous state, except in two kindreds in
which affected individuals were compound heterozygous for two
different variants in this gene. Mutations segregated with the disease
in all families (Fig. 2a,b,c) and were not detected in a panel of at
least 140 chromosomes from unrelated control individuals of
European or North African origin. All were predicted to cause early
protein truncation.
We found only two mutations in more than one pedigree
(Fig. 2a,b). We identified a homozygous 6100C-T substitution
(R2034X) in exon 32 in three consanguineous North African kindreds.
The predicted protein—if not rapidly degraded—would be truncated
by 27% of its normal size. A 5-bp deletion in exon 3 (529_533delA-
TATT) leading to a frameshift that should cause early termination at
amino acid residue 179 was homozygous in two Portuguese families.
The absence of linkage disequilibrium in previous studies8 might be
explained by the diversity of the mutations identified, but similar
haplotypes in Algerian and Portuguese families suggest regional
founder effects (Fig. 2a,b). We did not find any mutations in the
remaining family, but linkage was not conclusive in this family, either.
We examined a total of 22 individuals with mutations in the SPG11
gene at a mean age of 24.8 ± 9.5 years (range, 12–49). Onset of the
disease occurred between 2 and 23 years (mean age, 11.8 ± 5.5 years)
and consisted of either spastic gait (57%, 12/21 patients) or cognitive
impairment (19%, 4/21), sometimes diagnosed as mental retardation.
AfterB10 years of evolution, the full-blown clinical picture consisted
of progressive and severe spastic paraplegia
with distal wasting and cognitive problems
(Table 1). In several cases (n ¼ 6), cognitive
dysfunction clearly worsened with disease
progression. Cerebral imaging showed a
TCC accompanied by periventricular white
matter changes and cortical atrophy in the
majority of affected individuals. Pseudobul-
bar dysarthria was frequent (54%, n ¼ 12),
and dystonic voice was noted in one
individual. Notably, although electro-
myographic recordings were normal in a
few affected individuals, peripheral neuropa-
thy was frequent (72%, 13/18) and was mostly associated with pure
motor changes. We occasionally observed additional signs, such
as optic atrophy, retinitis pigmentosa, mild cerebellar signs, cataract
and clinodactyly.
The human SPG11 gene contains 40 exons on chromosome
15q21.1. The full-length 8-kb transcript encodes a predicted protein
of 2,443 amino acids of unknown function, which we termed
spatacsin, after ‘spasticity with thin or atrophied corpus callosum
syndrome protein’. The sequence of spatacsin has been strongly
conserved throughout evolution, with orthologs in mammals and
other vertebrates. Human SPG11 shares 85% identity with the
homologous protein in dog, 76% with mouse and 73% with rat.
Less similarity was found with homologous proteins of smaller
sizes in Fugu rubripes (44%), Tetraodon nigroviridis (39%) and
Drosophila melanogaster (22%).
Neither the gene nor the protein it is predicted to encode in many
species shows any significant sequence similarity to known cDNA or
protein sequences. At the protein level, spatacsin has very few known
domains, including four putative transmembrane signatures (Fig. 1c).
The level of hydrophobicity (34.2%) over the entire sequence was
typical of a globular protein, but a succession of globular domains is
more likely because of its size. However, hydrophobic cluster analysis15
identified only one small linker between amino acids 1410 and 1440.
This analysis also confirmed one of the putative transmembrane
regions at amino acids 200 to 240 that was found in four other
vertebrates, but not in tetraodon or D. melanogaster, in which the
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Figure 1 Critical region of SPG11. (a) Physical
map of human chromosome 15q15–21 with
selected genetic markers and the candidate
genes that were sequenced. Distances in Mb are
indicated relative to chromosome 15 according
to the Ensembl database. Markers defining
the reduced candidate interval are in bold.
# indicates that these genes (SEMA6D and
MAP1A) were analyzed in a previous study8.
4 and o indicate the orientation of the open
reading frame (ORF) of each gene. (b) Exon-
intron structure of the 101 kb of the KIAA1840
gene, also known as FLJ21439, with positions
of mutations identified in 11 SPG11 families.
(c) Several of the putative functional domains
(boxes) and their positions on the protein
sequence. Regions I and II correspond to
structurally similar domains based on their
hydrophobicity status analyzed with DrawHCA
software. Notably, this protein is assigned to
the aromatic compound dioxygenase superfamily
because of a 22% identity with the consensus
sequence between residues 2104 and
2381 (ref. 24).
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protein has a shortened N-terminal domain. A thorough search for
putative duplications brought to light two structurally similar regions
based on the hydrophobicity state (residues 560–700 and 2250–2390)
in all vertebrate homologs of the protein. In the human protein,
sequence identity between these two regions was 19% (Supplemen-
tary Fig. 3 online).
Because there is no antibody against endogenous spatacsin as of yet,
we examined its subcellular location by overexpression of a GFP fusion
protein in COS-7 cells. The fusion protein
had a diffuse and reticular cytosolic and peri-
nuclear distribution and was sometimes also
present in nuclei (Supplementary Fig. 4
online). Fluorescence was still detectable
after methanol fixation, suggesting that part
of this protein is associated with membranes
and/or the cytoskeleton. GFP-spatacsin
slightly colocalized with mitochondria (erab)
and endoplasmic reticulum (calnexin) but
not with Golgi structures (giantin, alpha-
COP), transport vesicles (Scamp1) or the
cytoskeleton (alpha-tubulin). Examination of
the endogenous protein with a specific anti-
body will refine the subcellular localization of
this new and very large protein.
Previous expression profiling of the SPG11
gene16 showed low but ubiquitous expression
in mouse tissues, including the brain and
structures apparently not related to the phe-
notype—a profile reported in other neuro-
degenerative diseases17. We successfully
amplified seven overlapping cDNA fragments
from the KIAA1840 mRNA extracted from
human cerebral cortex and used them to
probe human adult multiple-tissue RNA
blots. At least three alternative transcripts
were detected in all structures of adult
brain. The full-length transcript (B8 kb)
was most highly expressed in the cerebellum,
the B5-kb transcript in the cerebral cortex
(Fig. 3). Using RT-PCR, we identified a
4.8-kb transcript composed of exons 28–40
with retention of intron 29 and parts of
introns 27 and 28. Various sites of translation
initiation are possible in exon 30 that would
keep the protein sequence in the same phase
as the full-length protein. We cannot exclude
the possibility that other transcripts exist with
the same size but a different composition.
When we investigated the temporal and
regional expression of the rat KIAA1840
mRNA by in situ hybridization in rat brain,
it was undetectable in newborn rats (P1).
However, we did detect it in the cerebellum
from P6–P21. At adulthood (P68), it was
expressed throughout the brain (Fig. 4 and
Supplementary Figs. 5 and 6 online).
Expression was low, but stronger signals
were observed in the pineal gland, the edges
of the lateral ventricles, the granular layer of
the cerebellum and the hippocampus. In
contrast to human RNA blots, we detected
only weak expression in the cerebral cortex. Understanding the
function of spatacsin in these structures would help to explain the
major features of the disease phenotype: for example, expression in the
hippocampus could be related to the cognitive impairment observed
in affected individuals. In addition, it remains to be investigated
whether the labeling of the edges of the lateral ventricles (the location
of oligodendrocyte progenitors) is related to the white matter changes
in affected individuals.
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Figure 2 Pedigrees and segregation of the mutations detected in KIAA1840. Square symbols are
men, and circles are women. The filled symbols are affected individuals. The numbers are an internal
reference for each sampled individual. Asterisks indicate sampled subjects. m ¼ mutation; + ¼ wild
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is indicated. (c) Nonrecurrent mutations.
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Several lines of evidence suggest that KIAA1840 is responsible for
ARHSP-TCC: (i) its location in the recently refined SPG11 interval
(present study and refs. 7–9), (ii) the identification of gene mutations
that segregate in ten potentially linked families, (iii) the predicted
deleterious effects of the mutations on the protein and (iv) the
absence of the mutations in a panel of ethnically matched controls.
Furthermore, SPG11 seems to be the gene most frequently responsible
for ARHSP-TCC. Only a single family (8% in our cohort) did
not have a mutation in SPG11, indicating that there is at least one
other responsible gene. On the other hand, whether the SPG11
gene accounts for other clinical subtypes of ARHSP has yet to
be determined.
Spastic paraplegias are believed to result from a dying back of axons.
Mitochondrial metabolism, endosomal and trans-Golgi trafficking
and axonal transport have been implicated in several HSPs18.
Although the function of spatacsin remains unknown, the experi-
mental evidence that it is expressed in all tissues and is highly
conserved among species suggests that it has an essential biological
function. The possible presence of at least one transmembrane domain
suggests that spatacsin may be a receptor or transporter.
The identification of SPG11 as the gene responsible for ARHSP-
TCC will enable further studies on the natural history and clinical and
biological characteristics of this disease. In addition, future studies on
the normal function of spatacsin are likely to help to elucidate its
pathophysiology.
METHODS
Affected individuals and families. We studied 53 individuals, 22 of whom
were affected, from seven consanguineous and five non-consanguineous
families of French (n ¼ 3), Algerian (n ¼ 2), Italian (n ¼ 2), Portuguese
(n ¼ 2), Arab-Israeli (n ¼ 1), Moroccan (n ¼ 1) and Tunisian (n ¼ 1) origin.
All presented with a typical ARHSP-TCC phenotype defined by the combina-
tion of progressive spastic paraparesis associated with thin corpus callosum on
cerebral magnetic resonance imaging5. Six SPG11 families had previously been
reported with a limited set of analyzed markers5,7,8 and six were new. They were
selected from among 89 families with hereditary spastic paraparesis compatible
with recessive transmission collected in our neurogenetic reference center in
collaboration with the SPATAX network. We obtained blood samples from all
affected individuals and their relatives after they had given their informed
written consent in accordance with the local Paris-Necker Ethics Committee
(Supplementary Note). Genomic DNA was extracted from leukocytes using
standard procedures.
Linkage analyses. Genotypes at 34 microsatellites were determined by PCR
with a fluorescently labeled primer on an ABI-3730 sequencer (Applied
Biosystems) and GeneMapper 3.5 software (Applied Biosystems). Haplotypes
were constructed manually. Allegro 1.2c19 was used to calculate two-point and
multipoint LOD scores between the disease phenotype and each of the markers
or between the disease phenotype and the map of the markers, assuming
complete penetrance, equal allele frequencies for the markers and a frequency
of mutated alleles of 0.0005. Marker order and genetic distances were obtained
from the Ensembl and Marshfield databases (see URLs section below). The
genome scan in family FSP221 was performed using 400 microsatellites,
regularly spaced on all chromosomes (ABI-Prism linkage mapping set v2;
Applied Biosystems). We used 18 additional polymorphic markers to analyze
and exclude three locations other than chromosome 15q with initial multipoint
LOD scores of 2.2–2.5 (data not shown).
Mutation detection. Mutations in SPG7 (ref. 20) were excluded in all families;
SLC12A6 (ACCPN locus) and ACP33 (SPG21 locus) were ruled out in families
in which linkage extended to these regions on chromosome 15q12,14.
Primers were designed using Oligo6 (MBI) to amplify all coding exons with at
least 50 bp of intronic sequences of 16 genes in the SPG11 candidate interval
(Supplementary Table 1). PCR-amplified fragments of genomic DNA were
purified using exonuclease 1 (New England Biolabs, 2 units per 5 ml PCR pro-
duct) and antarctic phosphatase (New England Biolabs, 1 unit per 5 ml of PCR
product) and sequenced by the fluorescent dideoxy-terminator method (BigDye
v3.1, Applied Biosystems) on an automated ABI-3730 sequencer according to
the manufacturer’s recommendations. Sequences were aligned and compared
with consensus sequences with SeqScape 2.5 software (Applied Biosystems). The
positions of the mutations are indicated relative to the first ATG codon.
RNA blot analyses (human). Total RNA was extracted from the cerebral cortex
of a healthy individual, post-mortem (Brain Bank of INSERM U679), using the
RNeasy Mini kit (Qiagen). cDNAs were synthesized using random hexamers
and the Termoscript reverse transcriptase as recommended by the supplier
(Invitrogen). Seven 1.2-kb probes covering the KIAA1840 cDNA were amplified
by PCR at an annealing temperature of 60 1C (Supplementary Table 1).
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Figure 3 Expression profile of KIAA1840 examined by RNA blot in human
adult brain. The transcripts were present in all brain tissues. Note the 8-kb
transcript more intensely expressed in the cerebellum, whereas the 5-kb
transcript is mainly found in the cerebral cortex.
LV
HIP
DV3
PG
GrC
NeuN
labeling
AntisenseSense
Figure 4 Spatial expression of rat KIAA1840 in adult brain (P68) by in situ
hybridization with a pool of three antisense probes or a pool of three sense
probes. Note the labeling with the antisense probe in comparison with the
Neu-N neuronal specific counterstaining in adjacent slices. No specific
staining was observed with the sense probes. KIAA1840 expression was
low throughout the brain and was noted more particularly in the following
structures: LV, lateral ventricles; HIP, hippocampus; PG, pineal gland; GrC,
granular cell layer of the cerebellum; DV3, third ventricle. The same results
were obtained using the pool of three probes or each probe independently.
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A mixture of these probes were labeled with a-32P by random priming
(Prime-it II Random Primer Labeling Kit, Stratagene) and purified using
ProbeQuant G-50 micro columns (Amersham Biosciences, specific activity
Z 1  109 cpm/mg), were hybridized to human multiple-tissue RNA blots
(Clontech) and washed as recommended and were then exposed to X-ray film
for autoradiography.
Exon composition of the transcripts was determined by RT-PCR amplifica-
tion on total RNA from human cerebral cortex using a series of primer pairs
covering the whole cDNA and all introns (Supplementary Table 1). Alternative
transcripts were purified from agarose gels after electrophoresis and were
directly sequenced using appropriate primers.
In situ hybridization (rat). Young (P1, P6, P15 and P21, n ¼ 1 each) and adult
(P68, 200 g, n ¼ 2) Sprague-Dawley rats (Charles River) were killed by
decapitation, and their brains were rapidly extracted and frozen in isopentane
at –50 1C. Sections were cut every 600 mm on a cryostat (–20 1C) from the
medulla to the striatum (+1.7 mm from bregma according to the rat brain
coordinates of Paxinos & Watson), thaw-mounted on glass slides and stored at
–80 1C. KIAA1840 mRNA expression was analyzed with three antisense
oligonucleotides recognizing exons 15, 29 and 32, designed with Helios ETC
oligonucleotide design software (Helios Biosciences) from the mRNA sequence
(XM-242139) of Rattus norvegicus. Each oligonucleotide or a mix of the three
oligonucleotides gave identical results. A mix of three sense oligonucleotides
was used as negative control.
In situ hybridization was performed as described in ref. 21. Briefly,
oligonucleotides were labeled with [35S]dATP using terminal transferase
(Amersham Biosciences) to a specific activity of 5  108 dpm/mg. The day of
the experiment, slides were fixed in 4% formaldehyde in PBS, washed with PBS,
rinsed with water, dehydrated in 70% ethanol and air dried. Sections were then
covered with 140 ml of hybridization medium (Helios Biosciences) containing
3  105 to 5  105 dpm of the labeled oligonucleotide mix. Slides were
incubated overnight at 42 1C, washed and exposed to a BAS-SR Fujifilm
Imaging Plate for 5–10 d. The plates were scanned with a Fujifilm BioImaging
Analyzer BAS-5000 and analyzed with Multi Gauge Software (Fuji).
For double labeling experiments, brains were processed as for in situ
hybridization. After the last wash step, sections were fixed in 4% paraformal-
dehyde in PBS, preincubated in PBS containing 6% goat serum and 0.1%
triton, incubated in the same buffer with mouse antibodies against Neu-N
(Chemicon International, 1:250), followed by incubation in the same buffer
with biotinylated horse anti-mouse IgG antibodies and ABC reagents (Vector
Laboratories). Labeling was captured by emulsion autoradiography.
Bioinformatics. Functional domains were searched for using bioinformatics
tools available online at BABEL, Ressource Parisienne en Bioinformatique
Structurale and PSORT (see URLs section below). Psi-blast was used to look
for homologous proteins or peptides. Alignment of homologous proteins was
performed using CLUSTALW. DomHCA was used for a bidimensional
analysis of hydrophobicity15,22. CysState was used to predict the existence of
disulfide bridges23.
Overexpression studies. The KIAA1840 cDNA from clone pf01011 (Kazusa
DNA Research Institute) was excised from the pBluescript II SK(+) vector
using XhoI and NotI restriction enzymes and was cloned in fusion with EGFP in
a SalI/Bsp20I–digested pEGFP-C1 vector (Clontech). The construction was
verified by direct sequencing after ligation, transformation and plasmid
extraction using standard procedures.
COS-7 cells were maintained in DMEM (Invitrogen) supplemented with
10% FBS, penicillin (100 UI/ml) and streptomycin (100 mg/ml). Cells were
plated 24 h before transfection on cover slips coated with polyethylenimine and
transfected with Lipofectamine-PLUS reagents according to the manufacturer’s
instructions (Invitrogen). For six-well plates, 1–2 mg of plasmid DNA was used
per well. Cells were analyzed by immunofluorescence 48 h post-transfection.
The spatacsin-EGFP fusion protein was observed directly after a 15-min
fixation using either 4% formaldehyde, which preserves native structures
through cross-linking, or ice-cold methanol, which precipitates proteins
resulting in a loss of soluble proteins and increased detection of
structure-bound proteins. Immunocytochemistry was performed using classical
procedures with the following antibodies: mouse anti-alpha tubulin (1:400,
Sigma), rabbit anti-giantin (1:2,000, abcam), rabbit anti-calnexin (1:400,
Stressgen Bioreagents), mouse anti-erab (1:2,000, abcam), rabbit anti-scamp1
(1:400, Sigma) and rabbit anti-alpha-COP (1:1,000; Affinity Bioreagent). Cells
were counterstained with DAPI (1 mg/ml, Sigma) and mounted with Fluoro-
mount-G (Southern Biotech). Samples were observed with a Leica SP1 confocal
microscope. Leica confocal software was used to acquire the images.
Accession codes. NCBI: KIAA1840 homologs: human (NM_025137), dog
(XP_544657), chicken (XP_413940.1), mouse (BAE27954), rat (XP_242139.3).
Ensembl: KIAA1840 homologs: D. melanogaster (CG13531), Tetraodon
nigroviridis (GSTENG00003909001).
URLs. Ensembl: http://www.ensembl.org; Marshfield databases: http://
research.marshfieldclinic.org/genetics; BABEL: http://babel.infobiogen.fr:
1984/; Ressource Parisienne en Bioinformatique Structurale: http://bioserv.
rpbs.jussieu.fr/RPBS; PSORT: http://psort.nibb.ac.jp/; Psi-blast: http://
www.ncbi.nlm.nih.gov and CLUSTALW: http://www.ebi.ac.uk/clustalw/.
Note: Supplementary information is available on the Nature Genetics website.
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